Imprimis Pharma (IMMY) Misses Q1 EPS by 8c

Imprimis Pharma (NASDAQ: IMMY) reported Q1 EPS of ($0.33), $0.08 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $16 million versus the consensus estimate of $1.55 million.

For earnings history and earnings-related data on Imprimis Pharma (IMMY) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Laird Superfood, Inc. (LSF) Misses Q2 EPS by 22c ; Offers Guidance
• zSpace, Inc. (ZSPC) Reports Q2 results